Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L01FG01	MVASI	BioTech	Bevacizumab - 400mg/16ml	400mg/16ml	Injectable concentrate for solution	58,035,926 L.L
L01EE03	MEKTOVI	BioTech	Binimetinib - 15mg	15mg	Tablet, film coated	257,694,409 L.L
M03BC51	MUSCEROL EXTRA	G	Caffeine - 15mg, Paracetamol - 450mg, Orphenadrine citrate - 35mg		Tablet, scored	267,489 L.L
H05BA01	MIACALCIC	B	Calcitonin (salmon synthetic) - 100IU/ml	100IU/ml	Injectable solution	1,720,118 L.L
H05BA01	MIACALCIC 200 UI/ACTUATION	B	Calcitonin (salmon synthetic) - 200IU/actuation	200IU/actuation	Solution	5,399,559 L.L
S01EB02	MIOSTAT STERIL INTRAOCULAR	B	Carbachol - 0.01%	0.01%	Solution	8,117,591 L.L
R05CB03	MUCOTAL PEDIATRIQUE	G	Carbocysteine - 100mg/5ml	100mg/5ml	Syrup	298,205 L.L
R05CB03	MUCOTAL ADULTE	G	Carbocysteine - 250mg/5ml	250mg/5ml	Syrup	308,444 L.L
J01DD15	MINOCET	G	Cefdinir - 300mg	300mg	Capsule	1,407,003 L.L
J01DD08	MAGNACEF	G	Cefixime (trihydrate) - 100mg/5ml	100mg/5ml	Powder for suspension	349,399 L.L
J01DD08	MAGNACEF	G	Cefixime (trihydrate) - 100mg/5ml	100mg/5ml	Powder for suspension	700,142 L.L
J01DD08	MUREX	G	Cefixime (trihydrate) - 100mg/5ml	100mg/5ml	Powder for suspension	524,099 L.L
J01DD08	MUREX 200	G	Cefixime - 200mg	200mg	Capsule	430,030 L.L
J01DD08	MAGNACEF 400	G	Cefixime - 400mg	400mg	Capsule	1,307,559 L.L
J01DD08	MUREX	G	Cefixime - 400mg	400mg	Capsule	679,984 L.L
J01DD04	MEDAXONUM	G	Ceftriaxone (disodium) (Vial) - 500mg, Lidocaine (ampoule) -	500mg	Injectable powder for solution+diluent	307,740 L.L
J01DD04	MEDAXONUM	G	Ceftriaxone (disodium) - 1g	1g	Injectable powder for solution+diluent	438,093 L.L
J01DD04	MEDAXONUM	G	Ceftriaxone (disodium) - 1g	1g	Injectable powder for solution	15,482,229 L.L
J01DD04	MESPORIN-1000 IM	G	Ceftriaxone (sodium) - 1g	1,000mg	Injectable powder for solution+diluent	417,935 L.L
J01DD04	MESPORIN-1000 IV	G	Ceftriaxone (sodium) - 1g	1,000mg	Injectable powder for solution+diluent	417,935 L.L
J01DD04	MEGION-A	G	Ceftriaxone - 0.5g/2ml, Lidocaine (ampoule) -	0.5g/2ml	Injectable powder + solvent	355,840 L.L
J01DD04	MEGION-A	G	Ceftriaxone - 1g/3.5ml, Lidocaine (ampoule) -	1g/3.5ml	Injectable powder + solvent	623,468 L.L
J01DC02	MAXIL 750	G	Cefuroxime - 750mg	750mg	Injectable dry powder	159,917 L.L
D01AE14	MYCOSTER	B	Ciclopirox - 1%	1%	Cream	325,210 L.L
D01AE14	MYCOSTER	B	Ciclopirox - 8g/100g	8%	Film forming solution	756,583 L.L
D01AE14	MYCOSTER	B	Ciclopirox - 8g/100g	8%	Film forming solution	756,583 L.L
L01BB04	MAVENCLAD	B	Cladribine - 10mg	10mg	Tablet	200,244,812 L.L
L01BB04	MAVENCLAD	B	Cladribine - 10mg	10mg	Tablet	L.L
D10AF01	MEDACIN T	G	Clindamycin (phosphate) - 10mg/ml	10mg/ml	Solution	314,459 L.L
G01AF02	MICOTER GYNO OVULE	G	Clotrimazole - 500mg	500mg	Pessary	447,948 L.L

...